News
サブ-ナビゲーション
  • PICK UP
  • 現在位置:News
    • Notices
    • IR News
  • Corporate Information
  • Research & Development
  • Pipeline
  • Products
  • IR Information
  • Contact Us
  • Privacy Policy
  • Site Policy

News

  • May 15, 2025 Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2025 (JGAAP) pdf （214KB）
  • Apr 16, 2025 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （3,021KB）
  • Apr 11, 2025 Termination of License Agreement between TMRC and Syros Pharmaceuticals pdf （110KB）
  • Mar 31, 2025 FIMECS Completed a Joint Research Project with Astellas Pharma Inc. to Receive a Lump-sum Payment pdf （119KB）
  • Mar 25, 2025 Notice of Resolutions at the 17th Ordinary General Meeting of Shareholders pdf （90KB）
  • Mar 14, 2025 RaQualia Pharma and Nissan Chemical Enter into License Agreement to Research for Neurological Therapeutics pdf （137KB）
  • Mar 01, 2025 CONVOCATION NOTICE OF THE 17TH ORDINARY GENERAL MEETING OF SHAREHOLDERS pdf （208KB）
  • Feb 14, 2025 Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 (JGAAP) pdf （272KB）
  • Jan 07, 2025 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （2,550KB）
  • Jan 06, 2025 Sublicensing of Tegoprazan in Australia and New Zealand pdf （138KB）
  • Jan 01, 2025 Message from the President
  • Dec 18, 2024 Vetbiolix activates the option on the license for RQ-10 (VBX-3000) pdf （396KB）
  • Dec 13, 2024 Notice of Change in Representative Director pdf （154KB）
  • Dec 13, 2024 Notice Regarding Business Plan and Matters Concerning Growth Potential pdf （481KB）
  • Dec 13, 2024 Notice Regarding Revision to Consolidated Earnings Forecast for FY2024 pdf （291KB）
  • Dec 12, 2024 Launch of Tegoprazan in Latin America pdf （140KB）
  • Nov 14, 2024 Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2024 (JGAAP) pdf （209KB）
  • Nov 13, 2024 Syros Announced the Results of P3 Study for MDS pdf （143KB）
  • Oct 30, 2024 RaQualia Receives a Lump-Sum Payment from Hisamitsu Pharmaceutical pdf （133KB）
  • Oct 22, 2024 Marketing Approval of Tegoprazan in China for Helicobacter pylori Eradication Therapy pdf （123KB）
  • Oct 08, 2024 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （2,511KB）
  • Sep 26, 2024 Marketing Approval of Tegoprazan in Malaysia pdf （136KB）
  • Sep 02, 2024 Marketing Approval of Tegoprazan in Colombia pdf （122KB）
  • Aug 29, 2024 Eluracat®, a Ghrelin Receptor Agonist, Has Been Launched in France, and RaQualia Received a Lump-Sum Payment for Reaching a Milestone pdf （103KB）
  • Aug 14, 2024 Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2024 (JGAAP) pdf （214KB）
  • Aug 14, 2024 Syros Pharmaceuticals Announced Discontinuation of Enrollment in the Phase 2 Clinical Trial for Acute Myeloid Leukemia pdf （145KB）
  • Jun 25, 2024 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （2,486KB）
  • May 15, 2024 Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2024 (JGAAP) pdf （208KB）
  • May 15, 2024 Notice Concerning Non-operational Expenses pdf （129KB）
  • May 13, 2024 FIMECS Achieved an Initial Milestone in Joint Research with Astellas Pharma Inc. to Receive a Lump-sum Payment pdf （151KB）
  • May 08, 2024 Commencement of Phase I Clinical Trial for Novel TRPM8 Blocker in Australia pdf （84KB）
  • Apr 23, 2024 Tegoprazan will Expand its Presence in the Middle East and North Africa pdf （88KB）
  • Apr 10, 2024 Tamibarotene Received a U.S. FDA Fast Track Designation for the Treatment of Acute Myeloid Leukemia (AML) pdf （129KB）
  • Apr 04, 2024 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （2,661KB）
  • Apr 03, 2024 RaQualia Pharma and Velovia Pharma enter into an agreement to develop pet pharmaceuticals pdf （142KB）
  • Mar 26, 2024 Notice of Resolutions at the 16th Ordinary General Meeting of Shareholders pdf （87KB）
  • Mar 11, 2024 Notice on Approval to Initiate Phase 1 Clinical Trial of a Novel TRPM8 Blocker in Australia pdf （132KB）
  • Mar 08, 2024 Notice Concerning Syndicated Loan Agreement pdf （95KB）
  • Mar 02, 2024 CONVOCATION NOTICE OF THE 16TH ORDINARY GENERAL MEETING OF SHAREHOLDERS pdf （180KB）
  • Feb 20, 2024 Marketing Approval of Tegoprazan in Chile pdf （117KB）
  • Feb 14, 2024 Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 (JGAAP) pdf （307KB）
  • Feb 14, 2024 Acquisition of FIMECS by RaQualia Pharma pdf （204KB）
  • Dec 26, 2023 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （2,606KB）
  • Dec 15, 2023 Tegoprazan has been filed in China for Helicobacter pylori eradication therapy pdf （120KB）
  • Dec 14, 2023 RaQualia Pharma and Veritas In Silico announce that both companies have achieved the milestone in a joint research collaboration for mRNA-targeted small molecule drug discovery pdf （504KB）
  • Dec 08, 2023 Notice Regarding Revisions to Business Plan and Matters Concerning Growth Potential pdf （438KB）
  • Dec 08, 2023 Notice Regarding Revision to Consolidated Earnings Forecast for the Fiscal Year Ending December 31, 2023 pdf （261KB）
  • Nov 22, 2023 Tegoprazan Received Regulatory Approval for the Treatment of Duodenal Ulcers in China pdf （264KB）
  • Nov 10, 2023 Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2023 (JGAAP) pdf （207KB）
  • Oct 20, 2023 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （2,596KB）
  • Oct 16, 2023 Launch of Tegoprazan in Peru pdf （118KB）
  • Sep 04, 2023 Launch of Tegoprazan in Singapore pdf （134KB）
  • Aug 10, 2023 Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2023 (JGAAP) pdf （233KB）
  • Jul 28, 2023 Commencement of Phase 1 Clinical Trial of RQ-00202730, a Cannabinoid CB2 Receptor Agonist pdf （121KB）
  • Jul 24, 2023 Marketing Approval of Tegoprazan in Peru pdf （99KB）
  • Jul 10, 2023 Launch of Tegoprazan in Indonesia pdf （99KB）
  • Jul 07, 2023 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （2,510KB）
  • Jun 09, 2023 Termination of the Joint Research Agreement Regarding the Drug Discovery Targeting Specific Ion Channels pdf （181KB）
  • May 25, 2023 Launch of Tegoprazan in Mexico for the Treatment of Gastroesophageal Reflux Disease in Mexico pdf （144KB）
  • May 19, 2023 Oxford Cannabinoid Technologies Obtained Approvals to Initiate First-In-Human Clinical Trial for Cannabinoid CB2 Receptor Agonist in the United Kingdom pdf （123KB）
  • May 15, 2023 Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2023 (JGAAP) pdf （230KB）
  • Apr 25, 2023 RaQualia Pharma and leadXpro announce collaboration to accelerate drug discovery on intractable membrane protein targets pdf （175KB）
  • Apr 24, 2023 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （2,451KB）
  • Apr 06, 2023 RaQualia Pharma and Vetbiolix enter into an agreement to develop pet pharmaceuticals pdf （158KB）
  • Mar 24, 2023 Notice of Resolutions at the 15th Ordinary General Meeting of Shareholders pdf （85KB）
  • Mar 03, 2023 CONVOCATION NOTICE OF THE 15TH ORDINARY GENERAL MEETING OF SHAREHOLDERS pdf （227KB）
  • Mar 02, 2023 Convocation Notice of the 15th Ordinary General Meeting of Shareholders pdf （227KB）
  • Feb 14, 2023 Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2022 (JGAAP) pdf （311KB）
  • Dec 14, 2022 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （2,313KB）
  • Nov 11, 2022 Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2022 (JGAAP) pdf （248KB）
  • Sep 12, 2022 Shared Research, Inc. Issued an Analyst Report on RaQualia Pharma Inc. pdf （4,809KB）
  • Aug 15, 2022 Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (JGAAP) pdf （231KB）
  • May 13, 2022 Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2022 (JGAAP) pdf （226KB）
  • Mar 25, 2022 Notice of Resolutions at the 14th Ordinary General Meeting of Shareholders pdf （93KB）
  • Mar 07, 2022 Convocation Notice of the 14th Ordinary General Meeting of Shareholders pdf （203KB）
  • Feb 15, 2022 (Delayed)Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (JGAAP) pdf （307KB）
  • Feb 14, 2022 Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (JGAAP) pdf （307KB）
  • Dec 20, 2021 RaQualia Pharma and Hisamitsu Pharmaceutical have agreed to enter into a license agreement for a novel sodium channel blocker pdf （40KB）
  • Nov 12, 2021 Summary of Consolidated Financial Results for the First Nine Months of the Fiscal Year Ending December 31, 2021 (JGAAP) pdf （218KB）
  • Nov 01, 2021 RaQualia Pharma and ASKA Pharmaceutical Sign Joint Research Agreement pdf （130KB）
  • Sep 22, 2021 License Agreement for Novel TRPM8 Blocker pdf （109KB）
  • Sep 10, 2021 RaQualia Announces Milestone Payment from Syros pdf （119KB）
  • Aug 12, 2021 Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2021 (JGAAP) pdf （242KB）
  • Jul 28, 2021 Nav1.7 and Nav1.8 Sodium Channels Blocker (Amide Derivatives) Patent Allowance in the USA pdf （176KB）
  • Jun 21, 2021 Ghrelin Receptor Agonist (Serine Derivative) Patent Allowance in China pdf （244KB）
  • Jun 18, 2021 Potassium-Competitive Acid Blocker Patent Allowance in China pdf （273KB）
  • May 14, 2021 Summary of Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2021 (JGAAP) pdf （225KB）
  • May 07, 2021 RaQualia Announces Milestone Payment from Syros pdf （276KB）
  • Apr 02, 2021 Notice of Resolutions at the 13th Ordinary General Meeting of Shareholders pdf （93KB）
  • Apr 01, 2021 Conclusion of Agreement on the Establishment of a Joint Research Chair with Gifu Pharmaceutical University pdf （110KB）
  • Mar 31, 2021 Updated CEO's message
  • Mar 30, 2021 Notice of Entry into Grace Period Pertaining to Delisting of Company's Shares pdf （144KB）
  • Mar 25, 2021 Notice of Change of Representative Director and Change of Directors by Approval of Shareholder Proposals at Ordinary General Meeting of Shareholders pdf （138KB）
  • Mar 11, 2021 Investigator-Initiated Clinical Trial of Tamibarotene for Pancreatic Cancer Led by Nagoya University Approved as an Awarded Grant of the AMED Program; Promoting Clinical Trials for Development of New Drugs pdf （105KB）
  • Mar 10, 2021 Convocation Notice of the 13th Ordinary General Meeting of Shareholders pdf （341KB）
  • Mar 05, 2021 Syros Initiates a Phase III Clinical Trial of Tamibarotene in Combination with Azacitidine for Higher-Risk MDS pdf （126KB）
  • Mar 02, 2021 Receipt of Milestone Payment from Maruho pdf （117KB）
  • Feb 16, 2021 Corporate Growth Plan by the New Management pdf （746KB）
  • Feb 16, 2021 Business Plan Jan. 1, 2021 - Dec. 31, 2023 pdf （3,413KB）
  • Feb 12, 2021 Notice regarding the possibility that RaQualia's shares may become "a stock entering a probationary period related to delisting" pdf （152KB）
  • Feb 12, 2021 Notice of Changes in Executive Personnel of RaQualia pdf （185KB）
  • Feb 12, 2021 Summary of Consolidated Financial Results for the Fiscal Year Ended December 31, 2020 (JGAAP) pdf （271KB）
  • Feb 02, 2021 Selective TRPM8 Blocker (Azaspiro derivatives) Patent Allowance in China pdf （181KB）
  • Feb 02, 2021 Notice Regarding the Revision of the Medium-Term Management Plan pdf （190KB）
  • Feb 02, 2021 Notice Regarding the Recording of Non-Operating Revenues and Non-Operating Expenses (Foreign Exchange Losses) and Revision of the Full-Year Consolidated Earnings Forecast pdf （179KB）
  • Feb 01, 2021 New Drug Application for Tegoprazan in China pdf （145KB）
  • Jan 29, 2021 RaQualia Announces Receipt of Lump Sum Payment from Asahi Kasei Pharma as a Result of AK1780 License Agreement pdf （129KB）
  • Jan 22, 2021 Dissolution of Consolidated Subsidiary and Debt Waiver pdf （183KB）
  • Jan 12, 2021 TMRC Signed a Biomarker License Agreement with Syros Pharmaceuticals pdf （105KB）

  • CLOSE
  • MENU

サイト内検索

Cookie Policy

We use cookies to provide you with a better browsing experience.
Please confirm that you agree to our use of cookies by clicking Yes.
If you continue to browse this website even without agreeing to our use of cookies,
we consider that you have consented to our use of cookies.

Privacy Policy

Yes

  • footer-content
  • header-content
  • header-content